ResearcherJohns Hopkins UniversityActive in the last 2 years
Adrian Gerard Murphy
Matched on ORCID iD 0000-0002-9983-8641; OpenAlex author ID A5021680577. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 64
2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 8
- Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in adv… Co-author DOI 10.1186/s12885-025-14512-2↗
- Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
- A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1111/cts.12802↗
- Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/apc.2020.03.03↗
- IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. Co-author DOI 10.1172/jci124077↗
- Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
- Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. Co-author DOI 10.18632/oncotarget.22433↗
- Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methylation. Co-author DOI 10.1158/0008-5472.can-15-3264↗
Closest collaborators
The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lei Zheng · 6 shared papers, 2016–2021 · strength 0.50
- Paper Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenoca… DOI 10.21037/apc.2020.03.03↗
- Paper IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. DOI 10.1172/jci124077↗
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Stephen T. Muth · 2 shared papers, 2019–2020 · strength 0.25
- David J. Easty · 1 shared paper, 2026 · strength 0.23
- Derek Gerard Power · 1 shared paper, 2026 · strength 0.23
- Patrick Glyn Morris · 1 shared paper, 2026 · strength 0.23
- Bryan T. Hennessy · 1 shared paper, 2026 · strength 0.23
- Ray McDermott · 1 shared paper, 2026 · strength 0.23
- Alex B. Blair · 3 shared papers, 2017–2021 · strength 0.23
- Paper IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. DOI 10.1172/jci124077↗
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Nilofer Saba Azad · 3 shared papers, 2017–2021 · strength 0.22
- Paper A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. DOI 10.1111/cts.12802↗
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Elizabeth M. Jaffee · 3 shared papers, 2016–2021 · strength 0.20
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. DOI 10.18632/oncotarget.22433↗
- Paper Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methyla… DOI 10.1158/0008-5472.can-15-3264↗
- Victoria M. Kim · 2 shared papers, 2017–2019 · strength 0.15
- Mengni He · 1 shared paper, 2020 · strength 0.15
- Robert A. Anders · 2 shared papers, 2016–2021 · strength 0.13
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methyla… DOI 10.1158/0008-5472.can-15-3264↗
- Christopher L. Wolfgang · 2 shared papers, 2016–2021 · strength 0.13
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Cancer-Associated Fibroblasts in Pancreatic Cancer Are Reprogrammed by Tumor-Induced Alterations in Genomic DNA Methyla… DOI 10.1158/0008-5472.can-15-3264↗
- Agnieszka A. Rucki · 2 shared papers, 2016–2017 · strength 0.13
- Dung Thi Le · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Jin Peng He · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Ana De Jesus-Acosta · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Amy Hacker-Prietz · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Valerie Lee · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Ross C. Donehower · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Matthew John Weiss · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Amol Kumar Narang · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Elliot K. Fishman · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
- Ralph H. Hruban MD · 2 shared papers, 2017–2021 · strength 0.12
- Paper Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 20… DOI 10.1016/j.canlet.2020.10.039↗
- Paper Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic ca… DOI 10.1002/cam4.1104↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.